The week in pharma: action, reaction and insight – week to September 15, 2023
By Barbara Obstoj-Cardwell. Editor
Among last week’s notable news, US drug developer Crinetics Pharmaceuticals released surprisingly good Phase III clinical trial results for its paltusotine in acromegaly. Germany’s Immatics has entered into a collaboration with the USA’s Moderna to develop mRNA-based cancer therapies. US cell and gene based immune-oncology drug developer 2seventry bio last week announced it is cutting its work force by 40% as part of a cost-cutting restructuring, and that chief executive Nick Leschly is stepping down. Also of note, Alnylam received a positive US Food and Drug Administration (FDA) advisory committee vote for its ATTR-cardiomyopathy candidate Onpattro (patisiran).
Crinetics’ PATHFNDR-1 impressive Phase III data for paltusotine in acromegaly
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze